StudyRareStudyRare

Autosomal dominant polycystic kidney disease (ADPKD)

On ABGC's listListed on the ABGC Self-Study GuideLog in to star

Last updated Nov 3, 2026

Log in to add personal notes on this page.

A 35-year-old presents with hypertension and flank pain. Abdominal ultrasound reveals enlarged kidneys bilaterally with numerous cysts. His father had kidney failure at age 50.

AD; PKD1 (polycystin-1; ~78%) or PKD2 (polycystin-2; ~15%), with rarer genes or no identified gene in the remainder. Truncating variants likely act by loss of function; hypomorphic alleles often reduce functional protein, so their effect depends on the variant on the other allele.

  • PKD1: more severe, earlier ESRD (mean age 58)
  • PKD2: milder, later ESRD (mean age 75)

Polycystin-1 and polycystin-2 form one complex, three PC2 to one PC1, and the interaction is central to the maturation and localization of both. The complex sits in the primary cilium, so ADPKD is a ciliopathy. It probably acts as a sensor; whether Ca2+, cAMP, or G-protein signaling carries the message downstream is unsettled.

  • Allele type: in PKD1, truncating variants bring kidney failure at a mean 55.6 years versus 67.9 for nontruncating variants. Increasing evidence suggests that some hypomorphic nontruncating variants have a PC1 folding or trafficking defect. The well-studied hypomorphic allele p.Arg3277Cys gives few or no cysts in heterozygotes; in trans with a fully penetrant allele, a hypomorphic allele has caused prenatal-onset disease, and biallelic hypomorphic variants can mimic ARPKD.
  • Folding genes: GANAB, DNAJB11, ALG9, and ALG5 encode proteins that glycosylate, fold, or quality-check membrane proteins. PC1 maturation and trafficking are sensitive to their loss, and the kidney and liver cysts likely arise through disrupted PC1 trafficking.
  • Aneurysms: polycystins are also present in blood vessels, and reduced levels there are thought to underlie intracranial aneurysms.

Raised vasopressin may contribute to cyst formation, and tolvaptan, a vasopressin V2 receptor antagonist, slows kidney enlargement and the decline in kidney function.

  • Renal: Progressive cyst development, enlarged kidneys, ESRD
  • Hepatic: Liver cysts (common, usually asymptomatic)
  • Vascular: Intracranial aneurysms (5-10%), MVP
  • Other: Hypertension, hematuria, flank pain, nephrolithiasis
  • Ultrasound criteria (age-based cyst number)
  • Genetic testing (especially if family history uncertain)
  • Blood pressure control
  • Tolvaptan (vasopressin receptor antagonist) - slows progression
  • MRA screening for intracranial aneurysms (if family history or symptoms)

Reference Links